Phase 2 Lung Cancer Trial, Recruiting (NCT07218601)

Phase 2 Lung Cancer Trial, Recruiting NCT07218601 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07218601 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years of age or older
You have been diagnosed with early-stage non-small cell lung cancer (stage I) that has not yet been treated and can be removed with surgery
You have been diagnosed with a more advanced stage of non-small cell lung cancer (stages II to IIIB) that has not yet been treated and is planned to be treated with medication first, followed by surgery
You are generally able to carry out daily activities, with only mild limitations due to your condition (confirm with trial site)

Who may not be able to join:

There are no specific exclusion criteria listed in the provided information (confirm with trial site)

A note about this trial: The main test used in this study involves breathing into a device to collect a breath sample — nothing is injected or inserted into your body. Because of this, there are no requirements related to pregnancy or contraception for taking part.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gaetano Rocco, MD, Memorial Sloan Kettering Cancer Center

Phone: 212-639-3478

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07218601

Sponsor: Memorial Sloan Kettering Cancer Center

Phase: Phase 2

Status: Recruiting

Condition: Lung Cancer

Trial contact: 212-639-3478

More information: https://clinicaltrials.gov/study/NCT07218601

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years of age or older
You have been diagnosed with early-stage non-small cell lung cancer (stage I) that has not yet been treated and can be removed with surgery
You have been diagnosed with a more advanced stage of non-small cell lung cancer (stages II to IIIB) that has not yet been treated and is planned to be treated with medication first, followed by surgery
You are generally able to carry out daily activities, with only mild limitations due to your condition (confirm with trial site)

Who may not be able to join:

There are no specific exclusion criteria listed in the provided information (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

Registry

ClinicalTrials.gov

Start date

10 October 2025

Est. completion

1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

pathological response (Cohort 1: stages II to IIIB); progression (Cohort 1: stages II to IIIB); progression (Cohort 2: Stage I)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov